# A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)

> **NCT04669600** · PHASE2 · COMPLETED · sponsor: **Bioverativ, a Sanofi company** · enrollment: 12 (actual)

## Conditions studied

- Immune Thrombocytopenia (ITP)

## Interventions

- **DRUG:** SAR445088 (BIVV020)

## Key facts

- **NCT ID:** NCT04669600
- **Lead sponsor:** Bioverativ, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-04
- **Primary completion:** 2022-02-15
- **Final completion:** 2023-02-07
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04669600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04669600, "A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT04669600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*